Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry.
Arthur DarmonGregory DucrocqAdam JasilekLaurent FeldmanEmmanuel SorbetsRoberto FerrariIan FordJean-Claude TardifMichal TenderaKim M FoxPhillippe Gabriel StegPublished in: Clinical cardiology (2020)
Intermediate REACH RIS identified potential optimal candidates for adjunction of low-dose rivaroxaban while patients with low CHA2 DS2 VaSc score .appears unlikely to benefit from the COMPASS regimen. None of the three risk scores predicted the occurrence of serious bleeding.